

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) ~~An anticancer or an anti-metastatic agent for gene therapy containing A pharmaceutical composition for treating a solid tumor, or metastasis thereof, said composition comprising a gene carrier or cells harboring a gene encoding a recombinant protein consisting of human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene as an effective ingredient.~~
2. (Currently amended) The ~~agent composition~~ according to claim 1, wherein the LK68 gene comprises a nucleotide sequence represented by SEQ. ID. No. 1.
3. (Currently amended) The ~~agent composition~~ according to claim 1, wherein the gene carrier harboring the LK68 gene is a vector or a recombinant virus.
4. (Currently amended) The ~~agent composition~~ according to claim 3, wherein the vector is selected from ~~a group consisting of~~ a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.
5. (Currently amended) The ~~agent composition~~ according to claim 3, wherein the recombinant virus is selected from ~~a group consisting of~~ retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.
6. (Currently amended) The ~~agent composition~~ according to claim 1, wherein the cells are selected from ~~a group consisting of~~ hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells.

7. (Currently amended) The agent composition according to claim 1, wherein the gene carrier is selected from a group consisting of pSecTag-LK68, pLXSN-LK68, rAAV-LK68 and pAAV-LK68.

8. (Currently amended) The agent composition according to claim 1, wherein the LK8 gene comprises a nucleotide sequence represented by SEQ. ID. No. 2.

9. (Currently amended) The agent composition according to claim 1, wherein the gene carrier harboring the LK8 gene is a vector or a recombinant virus.

10. (Currently amended) The agent composition according to claim 9, wherein the vector is selected from a group consisting of a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.

11. (Currently amended) The agent composition according to claim 9, wherein the recombinant virus is selected from a group consisting of retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

12. (Currently amended) The agent composition according to claim 9, wherein the gene carrier is selected from a group consisting of pSecTag-LK8, pLXSN-LK8, rAAV-LK8 and pAAV-LK8.

13. (Currently amended) The agent composition according to claim 3, wherein the vector is included by 0.05 ~ 500 mg.

14. (Currently amended) The agent composition according to claim 3, wherein the recombinant virus is included by 10^3 - 10^{12} IU.

15. (Currently amended) The agent composition according to claim 1, wherein the cells are included by 10^3 - 10^8 e.a.

16. (Currently amended) The agent composition according to claim 1, wherein the cancer solid tumor is selected from ~~a group consisting of~~ colon carcinoma, liver cancer, lung cancer, breast cancer, brain tumor, prostatic carcinoma, skin cancer, stomach cancer, pancreas cancer, lymphoma, kidney cancer, ovarian cancer and metastatic tumor.

17. (Currently amended) The agent composition according to claim 16, wherein the cancer solid tumor is selected from ~~a group consisting of~~ colon carcinoma, liver cancer, lymphoma or and metastatic tumor.

18. (Currently amended) A method for ~~the~~ prevention or ~~the~~ treatment of a solid tumor, which includes a step of parenteral administration of the agent for gene therapy composition of claim 1 to an individual.

19. (Currently amended) The method according to claim 18, wherein the prevention or the treatment of a solid tumor is accomplished by ~~the~~ inhibition of ~~the~~ growth and ~~the~~ metastasis of the solid tumor.

20. (Currently amended) The method according to claim 18, wherein the administration of a gene carrier harboring human apolipoprotein(a) kringle KIV9-KIV10-K V (LK68) or K V (LK8) gene is accomplished by a method selected from ~~a group consisting of~~ chemical method, physical method, conjugation using liposome, a method using receptor and virus,~~etc.~~

21. (Currently amended) The method according to claim 18, wherein the administration is characterized by injecting cells selected from ~~a group consisting of~~ hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells transfected with human apolipoprotein(a) kringle KIV9-KIV10-KV(LK68) or KV(LK8) gene to a patient.

22. (Currently amended) The ~~agent~~ composition according to claim 9, wherein the vector is included by 0.05 ~ 500 mg.

23. (Currently amended) The ~~agent~~ composition according to claim 9, wherein the recombinant virus is included by 10^3 - 10^{12} IU.